Urology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging

This Phase 3 trial from the University of Alberta is comparing two imaging methods to improve early detection of prostate cancer. The study aims to find out whether high resolution micro-ultrasound or MRI better guides biopsy decisions, which could help reduce unnecessary procedures and improve diagnosis accuracy. Over 1200 men in multiple countries including the US and Canada are expected to take part.

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

Researchers at Baylor College of Medicine are testing a steroid cream applied twice a week to prevent repeated urinary tract infections in uncircumcised male infants. If this approach works, it could offer a simple and non-invasive way to lower infection rates and improve infant health. The study is currently enrolling participants in the United States.

BCG for Therapeutic Use Phase Ⅲ Clinical Trial

This Phase 3 study in China is investigating a therapeutic BCG vaccine aimed at preventing the return of non-muscle-invasive bladder cancer after surgery. Adults with intermediate or high-risk bladder cancer are being enrolled to see if this treatment can reduce recurrence safely and effectively. The outcome could provide a valuable option to improve long-term cancer control.

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

The UroGen Pharma trial is testing UGN-104, a new chemotherapy formulation delivered directly to the urinary tract for patients with low-grade upper tract urothelial cancer. This treatment could offer a less invasive alternative to surgery and traditional therapies, potentially lowering side effects. The study is recruiting about 70 patients across several countries including the United States.

Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

This trial is evaluating a non-invasive urine test called Cxbladder to detect urothelial carcinoma in patients who have microscopic blood in their urine. By potentially reducing the need for invasive cystoscopy, the test could make diagnosis easier and less uncomfortable. This study is recruiting 1000 participants in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.